FERDINANDOS SKOULIDIS to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.203
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
Score: 0.203
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.